Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304729 | 0.95 | POLB (0.41) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL3307429 | 0.86 | POLB (0.35) | ALDH1A1POLBMAPTALOX15NQO2 | |
| SCHEMBL12090531 | 0.77 | POLB (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL14739265 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL14739816 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL14739515 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL14740061 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL14739086 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL14740248 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 | |
| SCHEMBL15836237 | 0.75 | GRIA1 (0.52) | ALDH1A1POLBCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8765752-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2703393-A1 | CYCLIC AMIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2703394-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8629102-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8557766-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | SHIONOGI & CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2128134-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | Shionogi&Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | ALDH1A1 3399/4885POLB 4232/4885CA1 2700/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | ALDH1A1 3072/4885POLB 4161/4885CA1 2497/4885 |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | ALDH1A1 2526/4885POLB 4708/4885CA1 4070/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | ALDH1A1 2526/4885POLB 4708/4885CA1 4070/4885 |
| US-20100099676-A1 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 | MMP13, MMP3, MMP26 | ALDH1A1 469/4885POLB 3697/4885CA1 713/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | ALDH1A1 3218/4885POLB 4263/4885CA1 2739/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | ALDH1A1 2508/4885POLB 4734/4885CA1 4109/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | ALDH1A1 3127/4885POLB 4340/4885CA1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.